[ 177 Lu]Lu-PSMA-617-Mediated Endoradiotherapy of Triple-negative Breast Cancer by Targeting PSMA Expression on Tumor-Associated Neovasculature (EANM 2026) - Sep 29, 2026 - Abstract #EP-0055; "The therapeutic efficacy of [177Lu]LuPSMA617 in the 4T1 TNBC model strictly depends on specific PSMA binding and is not mediated by FAP crossreactivity. The radioligand acts primarily by damaging PSMApositive tumor vasculature, leading to DNA damage, apoptosis, and metabolic inhibition. These findings establish PSMA as a reliable vascular target for RLT in TNBC and support further clinical translation."
Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD31 • FOLH1 • PECAM1
|